Childbirth pain
Conditions
Interventions
Experimental group:0.1% ropivacaine + 0.33 µg/ml sufentanil, 0.15-0.25 ml/kg per body weight, pulse dosing
control group:0.1% ropivacaine with 0.33 µg/ml sufentanil, continuous infusion at a rate of 5-10 ml
Sponsors
Zhenxiong County People's Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Term singleton pregnancy (>=37 weeks), vertex presentation, primiparous or multiparous women voluntarily requesting labor analgesia, ASA classification I-II, without contraindications to neuraxial anesthesia.
Exclusion criteria
Exclusion criteria: Pregnant women and their families refuse, coagulation disorders, local or systemic infections, spinal deformities or surgical history, neurological conditions, hypovolemia or hypotension, allergy to local anesthetics, fetal distress or abnormal fetal position, or other obstetrician-recommended contraindications for delivery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| analgesic effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of times additional medication was administered and the total drug dosage;Labor duration;The onset times of the two drug groups; | — |
Countries
China
Contacts
Public ContactHu Xiuhong
Zhenxiong County People's Hospital
Outcome results
None listed